No shortcuts to SARS-CoV-2 antivirals
- 30 July 2021
- journal article
- editorial
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 373 (6554) , 488-489
Abstract
Are many drug repurposers pursuing artifacts?Keywords
This publication has 10 references indexed in Scilit:
- Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2Science, 2021
- Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial ResultsNew England Journal of Medicine, 2021
- Remdesivir for the Treatment of Covid-19 — Final ReportNew England Journal of Medicine, 2020
- What Are the Odds of Finding a COVID-19 Drug from a Lab Repurposing Screen?Journal of Chemical Information and Modeling, 2020
- The European Federation for Medicinal Chemistry (EFMC) Best Practice Initiative: Validating Chemical ProbesChemMedChem, 2020
- A SARS-CoV-2 protein interaction map reveals targets for drug repurposingNature, 2020
- Predicting the Risk of Phospholipidosis with in Silico Models and an Image-Based in Vitro ScreenMolecular Pharmaceutics, 2017
- Common pitfalls in preclinical cancer target validationNature Reviews Cancer, 2017
- Medicinal chemistry strategies to minimize phospholipidosis.Current Medicinal Chemistry, 2009
- Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: A case study with structurally related piperazinesExperimental and Toxicologic Pathology, 2004